Compare CAN & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAN | ASMB |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.0M | 440.0M |
| IPO Year | 2019 | 2010 |
| Metric | CAN | ASMB |
|---|---|---|
| Price | $0.42 | $27.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $3.21 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 9.1M | 61.2K |
| Earning Date | 05-19-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $63.64 | $274.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $7.76 |
| 52 Week High | $2.22 | $39.71 |
| Indicator | CAN | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 40.92 | 46.42 |
| Support Level | $0.43 | $27.10 |
| Resistance Level | $0.55 | $30.54 |
| Average True Range (ATR) | 0.03 | 1.41 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 25.79 | 33.71 |
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.